
Type 2 diabetes and obesity remain the focus of zzso drugs for zzso zzso Only one new class of agents zzso 4 zzso has been approved in this field for control of blood zzso in patients with type 2 zzso zzso progress has been made in the zzso of pathways of interest for new therapies in diabetes and zzso partly through advances in human zzso that have highlighted genetic zzso relevant to pancreatic beta cell dysfunction and zzso control of food zzso zzso zzso drugs targeting these pathways are in early clinical investigation, including zzso zzso zzso targeting zzso zzso and zzso zzso zzso also have emerged, including zzso of the zzso zzso and zzso 

